Physician profile
Cara Davis
NPI 1952338782
$17,503.16
in general payments reported to CMS, 2019-2025
66 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,490 · 2020: $2,632 · 2021: $3,132 · 2022: $2,757 · 2023: $2,234 · 2024: $2,248 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,491.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,212.13 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $2,158.52 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,611.08 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,335.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,074.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,043.62 | 2019-2025 | Jardiance, Stiolto Respimat |
| Amgen INC. | $964.08 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $756.97 | 2019-2025 | |
| Esperion Therapeutics, INC. | $505.85 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $433.47 | 2019-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $373.36 | 2019-2024 | |
| Axsome Therapeutics, INC. | $361.47 | 2023-2025 | Sunosi, Auvelity, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $336.70 | 2022-2025 | |
| Bausch Health US, LLC | $319.61 | 2020-2025 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $315.11 | 2020-2022 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.